Author:
Monte Andrew A,Brocker Chad,Nebert Daniel W,Gonzalez Frank J,Thompson David C,Vasiliou Vasilis
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Genetics,Molecular Biology,Molecular Medicine
Reference81 articles.
1. Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C: Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology. 2006, 70: 366-377. 10.1159/000098110.
2. Lee A, Ezzeldin H, Fourie J, Diasio R: Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy. Clin Adv Hematol Oncol. 2004, 2: 527-532.
3. Gaughan EM, Costa DB: Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol. 2011, 3: 113-125. 10.1177/1758834010397569.
4. Cappuzzo F, Finocchiaro G, Rossi E, Janne PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello F, Pressiani T, Destro A, Roncalli M, Crino L, Franklin WA, Santoro A, Varella-Garcia M: EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol. 2008, 19: 717-723. 10.1093/annonc/mdm492.
5. Monte AA, Heard KJ, Vasiliou V: Prediction of drug response and safety in clinical practice. J Med Toxicol. 2012, 8: 43-51. 10.1007/s13181-011-0198-7.
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献